LFVN241220P17500
- 0.00
- 0.000.00%
Lifevantage Newsroom
Express News | "Weight-Loss Drug Craze Appears To Be Curbing U.S. Obesity Epidemic; Obesity Is Down In The U.S. For The First Time In A Decade. A New Study Suggests Weight-Loss Drugs May Explain Why" - Bloomberg News
Express News | 'ADA Advises Against Using Compounded GLP-1 RA Medications' - Medscape
LifeVantage to Participate in the Water Tower Fireside Chat Series
LifeVantage Returns TrueScience Hydrating Lip Oil to U.S. Market
LifeVantage Unveils Lip Care Favorite Back for Cyber Monday
Returns On Capital Signal Tricky Times Ahead For LifeVantage (NASDAQ:LFVN)
LifeVantage (NASDAQ:LFVN) Is Posting Promising Earnings But The Good News Doesn't Stop There
LifeVantage's (NASDAQ:LFVN) Dividend Will Be $0.04
Here's Why We Think LifeVantage Corporation's (NASDAQ:LFVN) CEO Compensation Looks Fair
Lifevantage To Go Ex-Dividend On December 2nd, 2024 With 0.04 USD Dividend Per Share
Lifevantage Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Revenue Results.
LifeVantage Maintains Dividend at $0.04 per Share, Payable Dec. 16 to Shareholders of Record on Dec. 2
LifeVantage Corporation (LFVN) Q1 2025 Earnings Call Transcript Summary
LifeVantage Corporation (LFVN) Q1 2025 Earnings Call Transcript
Lifevantage: Fiscal Q1 Earnings Snapshot
Express News | Lifevantage Affirms FY2025 Adj EPS Guidance From $0.70-0.80 to $0.70-0.80 Vs $0.72 Est; Affirms FY2025 Sales Guidance From $200.00M-210.00M to $200.00M-210.00M Vs $204.80M Est
Lifevantage Q1 2025 Adj. EPS $0.15, Inline, Sales $47.214M Miss $49.800M Estimate
Express News | LifeVantage Corporation Released Encouraging Results From A Human Clinical Trial On Its New MindBody GLP-1 System. The Results Included A 140% Increase In GLP-1 Levels In The Body Leading To An Average Weight Loss of 9 Pounds In 8 Weeks And Up To 25...
Lifevantage | 8-K: LifeVantage Announces Financial Results for the First Quarter of Fiscal 2025
Lifevantage | 10-Q: Q1 2025 Earnings Report